Navigation Links
Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
Date:11/1/2010

MOUNTAIN VIEW, Calif., Nov. 1, 2010 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will report results for its fiscal quarter ended September 30, 2010, on Tuesday, November 9, 2010 following the close of the U.S. financial markets.  As the Company recently held an investor conference call on October 11th, there will not be a conference call held in conjunction with the release of the Company's third quarter results.  The Company will provide a regulatory update regarding its AZ-004 New Drug Application (NDA) after conducting a follow-on meeting with the U.S. Food and Drug Administration (FDA).

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials and submitted a New Drug Application in December 2009.  In October 2010, the Company received a Complete Response Letter (CRL) from the FDA, regarding its NDA for AZ-004.  A CRL is issued by FDA's Center for Drug Evaluation and Research indicating that the NDA review cycle is complete and the application is not ready for approval in its present form.  The Company is currently evaluating the FDA's comments in the CRL and anticipates meeting with the FDA before the end of the year to discuss the CRL.  For more information about Alexza, the Staccato technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

The anticipated news release will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 2016  Compass Diversified Holdings (NYSE: CODI ... of leading middle market businesses, announced today its consolidated ... 2016. First Quarter 2016 Highlights , ... or "Cash Flow") of $13.6 million for the first ... $15.0 million for the first quarter of 2016; ...
(Date:5/4/2016)... COUNTY, Calif. , May 4, 2016  It,s time for an upgrade. There ... shown on a brilliant 3.5 inch LCD, the illustrious DVMAXX HD  offers unparalleled ... brands as well as a world class manufacturer of innovative technology.  Photo ... ... ...
(Date:5/4/2016)... YORK , May 4, 2016 ... Share, Development, Growth and Demand Forecast to 2022 - Industry ... User (Hospital, Diagnostic Center and Others)" by P&S Market Research, ... $4,894.3 million in 2015, and it is expected to grow ... type, the high slice type segment is expected to witness ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Dermatologic surgeons performed nearly 10 million medically necessary ... percent since 2012. , The results of the 2015 ASDS Survey on Dermatologic Procedures ... cancer treatments and the growing popularity of soft-tissue fillers and body sculpting procedures. ...
(Date:5/5/2016)... GA (PRWEB) , ... May 05, 2016 , ... Liposuction ... (FDRS) 2016 Conference in St. Louis, Missouri at the Marriot St. Louis Airport Hotel. ... Byrd was chosen to address the conference about her unique specialization in treating Lipedema. ...
(Date:5/5/2016)... ... 2016 , ... Augusta Public Schools has teamed with CareDox to provide confidential ... health offices to streamline and bolster care for district students. , Augusta School ... public schools serve 2,300 students among its six schools. , Monica Guilliams, BSN, ...
(Date:5/5/2016)... ... ... Dental365 in Levittown opened just a few short months ago, but is ... with the patient’s comfort and convenience in mind. Located at 3254 Hempstead Turnpike ... routine and walk-in emergency dental care 365 days a year. And now they have ...
(Date:5/4/2016)... , ... May 05, 2016 , ... “Less than 15% ... Little City Executive Director. “As one of ten non-profit organizations to participate and complete ... of Light. The ultimate benefit is that for every $1 we invest in volunteer ...
Breaking Medicine News(10 mins):